All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Is there still a role in MM for auto-SCT after induction with a quadruplet combination?

During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Luciano J. Costa, University of Alabama at Birmingham, Birmingham, US. We asked, Is there still a role in multiple myeloma for autologous stem cell transplant (auto-SCT) after induction with a quadruplet combination?

Is there still a role in MM for auto-SCT after induction with a quadruplet combination?

In this video, Costa discusses the MASTER trial (NCT03224507), which involves the quadruplet drug combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (KRdD), followed by auto-SCT. The MASTER trial, updated during this congress, is critical to understand further how to implement minimal residual disease (MRD)-guided treatment decisions in the frontline setting and refine the use of auto-SCT.

 

Share: